3,4-dihydroxyphenylacetic acid has been researched along with Basal Ganglia Diseases in 6 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morales, I | 1 |
| Fuentes, A | 1 |
| Ballaz, S | 1 |
| Obeso, JA | 1 |
| Rodriguez, M | 1 |
| Tollefson, GD | 1 |
| Garvey, MJ | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Sheng, JG | 1 |
| Xu, DL | 1 |
| Yu, HZ | 1 |
| Xu, XR | 1 |
| Tang, QM | 1 |
| Waldmeier, PC | 1 |
| Huber, H | 1 |
| Heinrich, M | 1 |
| Stoecklin, K | 1 |
6 other studies available for 3,4-dihydroxyphenylacetic acid and Basal Ganglia Diseases
| Article | Year |
|---|---|
Striatal interaction among dopamine, glutamate and ascorbate.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Basal Ganglia Diseases; Chroma | 2012 |
The neuroleptic syndrome and central dopamine metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Female; Homo | 1984 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia | 1987 |
Discrimination of neuroleptics by means of their interaction with amfonelic acid: an attempt to characterize the test.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Corpus Striat | 1985 |